Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells

Hal Broxmeyer, G. W. Douglas, G. Hangoc, S. Cooper, J. Bard, D. English, M. Arny, L. Thomas, E. A. Boyse

Research output: Contribution to journalArticle

906 Citations (Scopus)

Abstract

The purpose of this study was to evaluate human umbilical cord blood as an alternative to bone marrow in the provision of transplantable stem/progenitor cells for hematopoietic reconstitution. Although no direct quantitative assay for human hematopoietic repopulating cells is at present available, the granulocyte-macrophage progenitor cell (CFU-GM) assay has been used with success as a valid indicator of engrafting capability. We examined >100 collections of human umbilical cord blood for their content of nucleated cells and granulocyte-macrophage, erythroid (BFU-E), and multipotential (CFU-GEMM) progenitor cells, in many cases both before and after cryopreservation. First it was determined that granulocyte-macrophage, erythroid, and multipotential progenitor cells remained functionally viable in cord blood untreated except for addition for anticoagulant for at least 3 days at 4°C or 25°C (room temperature), though not at 37°C, implying that these cells could be satisfactorily studied and used or cryopreserved for therapy after transport of cord blood by overnight air freight carriage from a remote obstetrical service. Granulocyte-macrophage progenitor cells from cord blood so received responded normally to stimulation by purified recombinant preparations of granulocyte-macrophage, granulocyte, and macrophage colony-stimulating factors and interleukin 3. The salient finding, based on analysis of 101 cord blood collections, is that the numbers of progenitor cells present in the low-density (<1.077 gm/ml) fraction after Ficoll/Hypaque separation typically fell within the range that has been reported for successful engraftment by bone marrow cells. Another observation of practical importance is that procedures to remove erythrocytes or granulocytes prior to freezing, and washing of thawed cells before plating, entailed large losses of progenitor cells, the yield of unwashed progenitor cells from unfractionated cord blood being many times greater. The provisional inference is that human umbilical cord blood from a single individual is typically a sufficient source of cells for autologous (syngeneic) and for major histocompatibility complex-matched allogeneic hematopoietic reconstitution.

Original languageEnglish
Pages (from-to)3828-3832
Number of pages5
JournalProceedings of the National Academy of Sciences of the United States of America
Volume86
Issue number10
StatePublished - 1989

Fingerprint

Hematopoietic Stem Cells
Fetal Blood
Stem Cells
Granulocytes
Granulocyte-Macrophage Progenitor Cells
Erythroid Precursor Cells
Macrophages
Diatrizoate
Myeloid Progenitor Cells
Ficoll
Interleukin-3
Cryopreservation
Granulocyte-Macrophage Colony-Stimulating Factor
Major Histocompatibility Complex
Bone Marrow Cells
Anticoagulants
Freezing
Erythrocytes
Bone Marrow
Air

ASJC Scopus subject areas

  • General
  • Genetics

Cite this

Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. / Broxmeyer, Hal; Douglas, G. W.; Hangoc, G.; Cooper, S.; Bard, J.; English, D.; Arny, M.; Thomas, L.; Boyse, E. A.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 86, No. 10, 1989, p. 3828-3832.

Research output: Contribution to journalArticle

Broxmeyer, H, Douglas, GW, Hangoc, G, Cooper, S, Bard, J, English, D, Arny, M, Thomas, L & Boyse, EA 1989, 'Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells', Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 10, pp. 3828-3832.
Broxmeyer, Hal ; Douglas, G. W. ; Hangoc, G. ; Cooper, S. ; Bard, J. ; English, D. ; Arny, M. ; Thomas, L. ; Boyse, E. A. / Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. In: Proceedings of the National Academy of Sciences of the United States of America. 1989 ; Vol. 86, No. 10. pp. 3828-3832.
@article{049f5bc1eca34ea8b2397ca98f238ea1,
title = "Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells",
abstract = "The purpose of this study was to evaluate human umbilical cord blood as an alternative to bone marrow in the provision of transplantable stem/progenitor cells for hematopoietic reconstitution. Although no direct quantitative assay for human hematopoietic repopulating cells is at present available, the granulocyte-macrophage progenitor cell (CFU-GM) assay has been used with success as a valid indicator of engrafting capability. We examined >100 collections of human umbilical cord blood for their content of nucleated cells and granulocyte-macrophage, erythroid (BFU-E), and multipotential (CFU-GEMM) progenitor cells, in many cases both before and after cryopreservation. First it was determined that granulocyte-macrophage, erythroid, and multipotential progenitor cells remained functionally viable in cord blood untreated except for addition for anticoagulant for at least 3 days at 4°C or 25°C (room temperature), though not at 37°C, implying that these cells could be satisfactorily studied and used or cryopreserved for therapy after transport of cord blood by overnight air freight carriage from a remote obstetrical service. Granulocyte-macrophage progenitor cells from cord blood so received responded normally to stimulation by purified recombinant preparations of granulocyte-macrophage, granulocyte, and macrophage colony-stimulating factors and interleukin 3. The salient finding, based on analysis of 101 cord blood collections, is that the numbers of progenitor cells present in the low-density (<1.077 gm/ml) fraction after Ficoll/Hypaque separation typically fell within the range that has been reported for successful engraftment by bone marrow cells. Another observation of practical importance is that procedures to remove erythrocytes or granulocytes prior to freezing, and washing of thawed cells before plating, entailed large losses of progenitor cells, the yield of unwashed progenitor cells from unfractionated cord blood being many times greater. The provisional inference is that human umbilical cord blood from a single individual is typically a sufficient source of cells for autologous (syngeneic) and for major histocompatibility complex-matched allogeneic hematopoietic reconstitution.",
author = "Hal Broxmeyer and Douglas, {G. W.} and G. Hangoc and S. Cooper and J. Bard and D. English and M. Arny and L. Thomas and Boyse, {E. A.}",
year = "1989",
language = "English",
volume = "86",
pages = "3828--3832",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "10",

}

TY - JOUR

T1 - Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells

AU - Broxmeyer, Hal

AU - Douglas, G. W.

AU - Hangoc, G.

AU - Cooper, S.

AU - Bard, J.

AU - English, D.

AU - Arny, M.

AU - Thomas, L.

AU - Boyse, E. A.

PY - 1989

Y1 - 1989

N2 - The purpose of this study was to evaluate human umbilical cord blood as an alternative to bone marrow in the provision of transplantable stem/progenitor cells for hematopoietic reconstitution. Although no direct quantitative assay for human hematopoietic repopulating cells is at present available, the granulocyte-macrophage progenitor cell (CFU-GM) assay has been used with success as a valid indicator of engrafting capability. We examined >100 collections of human umbilical cord blood for their content of nucleated cells and granulocyte-macrophage, erythroid (BFU-E), and multipotential (CFU-GEMM) progenitor cells, in many cases both before and after cryopreservation. First it was determined that granulocyte-macrophage, erythroid, and multipotential progenitor cells remained functionally viable in cord blood untreated except for addition for anticoagulant for at least 3 days at 4°C or 25°C (room temperature), though not at 37°C, implying that these cells could be satisfactorily studied and used or cryopreserved for therapy after transport of cord blood by overnight air freight carriage from a remote obstetrical service. Granulocyte-macrophage progenitor cells from cord blood so received responded normally to stimulation by purified recombinant preparations of granulocyte-macrophage, granulocyte, and macrophage colony-stimulating factors and interleukin 3. The salient finding, based on analysis of 101 cord blood collections, is that the numbers of progenitor cells present in the low-density (<1.077 gm/ml) fraction after Ficoll/Hypaque separation typically fell within the range that has been reported for successful engraftment by bone marrow cells. Another observation of practical importance is that procedures to remove erythrocytes or granulocytes prior to freezing, and washing of thawed cells before plating, entailed large losses of progenitor cells, the yield of unwashed progenitor cells from unfractionated cord blood being many times greater. The provisional inference is that human umbilical cord blood from a single individual is typically a sufficient source of cells for autologous (syngeneic) and for major histocompatibility complex-matched allogeneic hematopoietic reconstitution.

AB - The purpose of this study was to evaluate human umbilical cord blood as an alternative to bone marrow in the provision of transplantable stem/progenitor cells for hematopoietic reconstitution. Although no direct quantitative assay for human hematopoietic repopulating cells is at present available, the granulocyte-macrophage progenitor cell (CFU-GM) assay has been used with success as a valid indicator of engrafting capability. We examined >100 collections of human umbilical cord blood for their content of nucleated cells and granulocyte-macrophage, erythroid (BFU-E), and multipotential (CFU-GEMM) progenitor cells, in many cases both before and after cryopreservation. First it was determined that granulocyte-macrophage, erythroid, and multipotential progenitor cells remained functionally viable in cord blood untreated except for addition for anticoagulant for at least 3 days at 4°C or 25°C (room temperature), though not at 37°C, implying that these cells could be satisfactorily studied and used or cryopreserved for therapy after transport of cord blood by overnight air freight carriage from a remote obstetrical service. Granulocyte-macrophage progenitor cells from cord blood so received responded normally to stimulation by purified recombinant preparations of granulocyte-macrophage, granulocyte, and macrophage colony-stimulating factors and interleukin 3. The salient finding, based on analysis of 101 cord blood collections, is that the numbers of progenitor cells present in the low-density (<1.077 gm/ml) fraction after Ficoll/Hypaque separation typically fell within the range that has been reported for successful engraftment by bone marrow cells. Another observation of practical importance is that procedures to remove erythrocytes or granulocytes prior to freezing, and washing of thawed cells before plating, entailed large losses of progenitor cells, the yield of unwashed progenitor cells from unfractionated cord blood being many times greater. The provisional inference is that human umbilical cord blood from a single individual is typically a sufficient source of cells for autologous (syngeneic) and for major histocompatibility complex-matched allogeneic hematopoietic reconstitution.

UR - http://www.scopus.com/inward/record.url?scp=0345537461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345537461&partnerID=8YFLogxK

M3 - Article

C2 - 2566997

AN - SCOPUS:0345537461

VL - 86

SP - 3828

EP - 3832

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 10

ER -